Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow GT Biopharma, Inc.

Get SEC filing alerts via email and in your feed for GT Biopharma, Inc.

GTBP

GT Biopharma, Inc.

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing immuno-oncology therapies using proprietary Tri-specific and Tetra-specific Killer Engager platforms. Its products harness natural killer (NK) cells to target various cancers, including hematologic malignancies and solid tumors. The company focuses on innovative, scalable immunotherapies with potential for monotherapy or combination use, relying on strategic partnerships, intellectual property, and third-party manufacturing.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from GT Biopharma, Inc.

1
1
GT Biopharma, Inc. GT Biopharma Reports $2.8 Million Net Loss in Q1 2026, Zero Revenue

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
GT Biopharma, Inc. GT Biopharma Reports $28.4 Million Net Loss for Fiscal Year 2025 Amid Clinical Progress

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
GT Biopharma, Inc. GT Biopharma Reports $3.1 Million Net Loss in Q3 2025, Improved Financial Position

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
GT Biopharma, Inc. GT Biopharma Reports Improved Financial Results with Reduced Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
GT Biopharma, Inc. GT Biopharma Reports Improved Net Loss of $776,000 in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
GT Biopharma, Inc. GT Biopharma Reports $13.2 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
GT Biopharma, Inc. GT Biopharma Reports Mixed Financial Results, Net Loss, and Ongoing Challenges in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments